Hereditary papillary renal cell carcinoma
GPTKB entity
Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:disease
|
| gptkbp:associated_with |
gptkb:healthcare_access
palliative care patient education quality of life research studies advocacy efforts biomarkers clinical trials genetic testing patient rights public awareness campaigns research funding risk assessment health disparities healthcare policies insurance coverage medical education genetic counseling psychosocial support tumor microenvironment social determinants of health angiogenesis metastasis end-of-life care patient support groups clinical management economic burden treatment guidelines treatment costs immune evasion clinical trials participation long-term follow-up professional guidelines epithelial-mesenchymal transition screening recommendations tumor markers chromosome 7 abnormalities surveillance strategies other cancers MET gene mutations bilateral tumors chromosome 3 abnormalities family screening kidney tumors multifocality renal dysfunction |
| gptkbp:characterized_by |
papillary architecture
|
| gptkbp:death |
depends on stage
|
| gptkbp:diagnosis |
variable
imaging studies |
| gptkbp:first_described_by |
1990s
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hereditary papillary renal cell carcinoma
|
| gptkbp:inherits_from |
autosomal dominant
|
| gptkbp:is_common_in |
familial cases
|
| gptkbp:pathological_type |
Type 1
Type 2 |
| gptkbp:premiered_on |
30s to 50s
|
| gptkbp:prevalence |
rare
|
| gptkbp:risk_factor |
obesity
family history smoking |
| gptkbp:symptoms |
hematuria
flank pain |
| gptkbp:treatment |
gptkb:surgery
targeted therapy |
| gptkbp:bfsParent |
gptkb:Kidney_Cancer
|
| gptkbp:bfsLayer |
7
|